Literature DB >> 26792801

CTL-Promoting Effects of IL-21 Counteract Murine Lupus in the Parent→F1 Graft-versus-Host Disease Model.

Vinh Nguyen1, Horea Rus2, Ching Chen3, Violeta Rus4.   

Abstract

IL-21 promotes B cell and CTL responses in vivo, conferring IL-21 with a role in both humoral and cellular responses. Because CTL can target and eliminate autoreactive B cells, we investigated whether IL-21R signaling in CD8 T cells would alter the expansion of autoreactive B cells in an autoimmune setting. We addressed this question using the parent→F1 murine model of acute and chronic (lupus-like) graft-versus-host disease (GVHD) as models of a CTL-mediated or T-dependent B cell-mediated response, respectively. Induction of acute GVHD using IL-21R-deficient donor T cells resulted in decreased peak donor CD8 T cell numbers and decreased CTL effector function due to impaired granzyme B/perforin and Fas/Fas ligand pathways and a phenotype of low-intensity chronic GVHD with persistent host B cells, autoantibody production, and mild lupus-like renal disease. CTL effector maturation was critically dependent on IL-21R signaling in Ag-specific donor CD8, but not CD4, T cells. Conversely, treatment of DBA/2J→F1 chronic GVHD mice with IL-21 strongly promoted donor CD8 T cell expansion and rescued defective donor anti-host CTLs, resulting in host B cell elimination, decreased autoantibody levels, and attenuated renal disease, despite evidence of concurrently enhanced CD4 help for B cells and heightened B cell activation. These results demonstrate that, in the setting of lupus-like CD4 T cell-driven B cell hyperactivity, IL-21 signaling on Ag-specific donor CD8 T cells is critical for CTL effector maturation, whereas a lack of IL-21R downregulates CTL responses that would otherwise limit B cell hyperactivity and autoantibody production.
Copyright © 2016 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26792801     DOI: 10.4049/jimmunol.1501824

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

Review 1.  An update on lupus animal models.

Authors:  Wei Li; Anton A Titov; Laurence Morel
Journal:  Curr Opin Rheumatol       Date:  2017-09       Impact factor: 5.006

2.  RGC-32 Promotes Th17 Cell Differentiation and Enhances Experimental Autoimmune Encephalomyelitis.

Authors:  Violeta Rus; Vinh Nguyen; Alexandru Tatomir; Jason R Lees; Armugam P Mekala; Dallas Boodhoo; Cosmin A Tegla; Irina G Luzina; Paul A Antony; Cornelia D Cudrici; Tudor C Badea; Horea G Rus
Journal:  J Immunol       Date:  2017-03-29       Impact factor: 5.422

Review 3.  Orchestrated Cytokines Mediated by Biologics in Psoriasis and Its Mechanisms of Action.

Authors:  Aina Akmal Mohd Noor; Maryam Azlan; Norhanani Mohd Redzwan
Journal:  Biomedicines       Date:  2022-02-20

4.  A MLR-Based Approach to Analyze Regulators of T Lymphocyte Activation In Vivo.

Authors:  Jiří Koutník; Victoria Klepsch; Maria Pommermayr; Nikolaus Thuille; Gottfried Baier; Kerstin Siegmund
Journal:  Int J Mol Sci       Date:  2022-05-10       Impact factor: 6.208

5.  Prophylactic and Therapeutic Effects of Interleukin-2 (IL-2)/Anti-IL-2 Complexes in Systemic Lupus Erythematosus-Like Chronic Graft-Versus-Host Disease.

Authors:  Stefan Heiler; Jonas Lötscher; Matthias Kreuzaler; Johanna Rolink; Antonius Rolink
Journal:  Front Immunol       Date:  2018-04-04       Impact factor: 7.561

Review 6.  Association of Viral Infection With the Development and Pathogenesis of Systemic Lupus Erythematosus.

Authors:  Shigeru Iwata; Yoshiya Tanaka
Journal:  Front Med (Lausanne)       Date:  2022-02-25

Review 7.  New developments implicating IL-21 in autoimmune disease.

Authors:  Heather M Ren; Aron E Lukacher; Ziaur S M Rahman; Nancy J Olsen
Journal:  J Autoimmun       Date:  2021-07-02       Impact factor: 14.511

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.